Stockreport

AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Atai Beckley N.V - Common Shares  (ATAI) 
US:NASDAQ Investor Relations: ir.atai.net.cn
PDF BPL-003 (mebufotenin benzoate nasal spray) granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for treatment-resistant depression (TR [Read more]